ReviewDiagnostics (Basel, Switzerland)2025
The Emerging Biomarkers in Chronic Obstructive Pulmonary Disease: A Narrative Review.
Review in Diagnostics (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Breathing insights: Biomarkers as tools for chronic obstructive pulmonary disease assessment - A systematic review.Indian journal of pharmacology · 2026Pooled it
- Current Clinical Perspectives of Biomarkers in Respiratory Diseases: A Narrative Review.Journal of clinical medicine · 2026Review
- Effects of Fine Particulate Matter on Systemic Inflammatory Biomarkers in Elderly Patients with Chronic Obstructive Pulmonary Disease Versus the Healthy Elderly: A Pilot Study.International journal of molecular sciences · 2026Article
- Diagnostic value of ocular imaging biomarkers in chronic obstructive pulmonary disease: a multicenter prospective cross-sectional study.Journal of thoracic disease · 2026Article
- Bidirectional Clinical Interactions among Exacerbations and Comorbidities in COPD: A Narrative Review.Seminars in respiratory and critical care medicine · 2026Review
- The Nose-Lung Axis in Chronic Obstructive Pulmonary Disease: An Emerging Interface for Clinical Endotyping, Biomarker Discovery, and Integrated Management.Diagnostics (Basel, Switzerland) · 2026Article
- The Evolving Landscape of COPD Typization.Medicina (Kaunas, Lithuania) · 2026Review
- Unknotting the crosstalk between COPD and neuroinflammation.Journal of neuroinflammation · 2026Review
- Short-Term Effects of Dupilumab in Eosinophilic COPD.Journal of clinical medicine · 2026Article
- Biomarkers of pulmonary fibrosis in bronchoalveolar lavage fluid and saliva. Study methods and pathophysiological significance.Frontiers in medicine · 2026Review
- Clinical Disease Burden in Patients with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation in Japan: A Retrospective Database Analysis (EUROS Study).International journal of chronic obstructive pulmonary disease · 2026Article
- Development of a Bedside Decision Tree for Postexacerbation Risk Stratification: Translating Neuroimmune Biomarker Dynamics Into Clinical Practice.Canadian respiratory journal · 2026Observational
- Review on biological active metabolites of Astragali radix and its mechanisms in treating allergic respiratory diseases.Frontiers in pharmacology · 2026Review
- A Multimodal AI Framework for Automated Multiclass Lung Disease Diagnosis from Respiratory Sounds with Simulated Biomarker Fusion and Personalized Medication Recommendation.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The burden of chronic obstructive pulmonary disease (COPD) is increasing, especially for women in low-to-middle income countries. Biomarkers provide ever-increasing diagnostic precision for COPD and show promise for primary, secondary, and tertiary disease prevention. This review describes emerging applications for biomarkers in COPD, especially as they align with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) emphasis on prevention, early diagnosis, and response to therapy. These biomarkers include blood eosinophils; IgE; C-reactive protein; fibrinogen; procalcitonin; interleukins 6, 8, and 33; tumor necrosis factor alpha; and soluble receptor for advanced glycated products (sRAGE). They have been used in various ways to identify COPD endotypes, predict exacerbations, predict mortality, and monitor the response to therapy. The fraction of exhaled nitric oxide (FENO) is increasingly studied in eosinophilic COPD endotypes and can be a diagnostic and predictive non-invasive biomarker. Imaging biomarkers, especially the quantitative computerized tomography (QCT) assessment of airway remolding, functional small airway disease, air trapping, lung function, and volume surrogates, all serve as non-invasive biomarkers for screening, early detection, and disease progression. Biomarkers facilitate all the phases of COPD care from detecting early airflow obstruction to predicting exacerbation and mortality. Biomarkers will be increasingly used as precise diagnostic tools to improve the COPD outcomes. The aim of this narrative review is to summarize the recent investigations in COPD biomarkers and their clinical applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.